Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date: April 28, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $130.16M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.21 | 3.30%
Avg Daily Range (30 D): $0.10 | 4.85%
Avg Daily Range (90 D): $0.16 | 3.80%
Institutional Daily Volume
Avg Daily Volume: .48M
Avg Daily Volume (30 D): 2.41M
Avg Daily Volume (90 D): 1.19M
Trade Size
Avg Trade Size (Sh.): 143
Avg Trade Size (Sh.) (30 D): 195
Avg Trade Size (Sh.) (90 D): 151
Institutional Trades
Total Inst.Trades: 425
Avg Inst. Trade: $1.74M
Avg Inst. Trade (30 D): $3.19M
Avg Inst. Trade (90 D): $1.42M
Avg Inst. Trade Volume: .23M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.92M
Avg Closing Trade (30 D): $3.19M
Avg Closing Trade (90 D): $2.09M
Avg Closing Volume: 252.61K
       
News
May 15, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating Organ...
Source: N/A
May 3, 2025 @ 11:18 AM
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:...
Source: N/A
Apr 29, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating TechT...
Source: N/A
Apr 27, 2025 @ 12:20 PM
ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NAS...
Source: N/A
Apr 25, 2025 @ 4:57 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: N/A
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $-.17 $-.25
Diluted EPS $-.17 $-.25
Revenue $ $ $
Gross Profit $ $ $
Net Income / Loss $ $ -9.93M $ -15.11M
Operating Income / Loss $ $ -10.43M $ -16.14M
Cost of Revenue $ $ $
Net Cash Flow $ $ -4.18M $ -2.91M
PE Ratio